tranexamic acid has been researched along with Brain Injuries, Traumatic in 70 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Brain Injuries, Traumatic: A form of acquired brain injury which occurs when a sudden trauma causes damage to the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To summarize current literature evaluating tranexamic acid in the management of intracranial bleeding associated with traumatic and nontraumatic brain injuries and implications for clinical practice." | 9.69 | Therapeutic review: The role of tranexamic acid in management of traumatic brain injury, nontraumatic intracranial hemorrhage, and aneurysmal subarachnoid hemorrhage. ( Crowley, KL; Groth, CM; Sigmon, J, 2023) |
| " This study investigates whether out-of-hospital TXA use is associated with adverse events or unfavorable outcomes in suspected traumatic brain injury (TBI) when intracranial hemorrhage (ICH) is absent on initial computed tomography." | 7.11 | Tranexamic acid is not inferior to placebo with respect to adverse events in suspected traumatic brain injury patients not in shock with a normal head computed tomography scan: A retrospective study of a randomized trial. ( Dewey, EN; Harmer, JW; Meier, EN; Rowell, SE; Schreiber, MA, 2022) |
| "To summarize current literature evaluating tranexamic acid in the management of intracranial bleeding associated with traumatic and nontraumatic brain injuries and implications for clinical practice." | 5.69 | Therapeutic review: The role of tranexamic acid in management of traumatic brain injury, nontraumatic intracranial hemorrhage, and aneurysmal subarachnoid hemorrhage. ( Crowley, KL; Groth, CM; Sigmon, J, 2023) |
| "Tranexamic acid (TXA) has been shown clinically to reduce mortality in hemorrhaging and head-injured trauma patients and has the potential to mitigate secondary brain injury with its reported antifibrinolytic and antiinflammatory properties." | 5.46 | Impact of tranexamic acid on coagulation and inflammation in murine models of traumatic brain injury and hemorrhage. ( Boudreau, RM; Caldwell, CC; Friend, LA; Goetzman, H; Goodman, MD; Johnson, M; Makley, AT; Pritts, TA; Veile, R, 2017) |
| "To determine the effect of Intravenous Tranexamic Acid (TXA) on traumatic intracerebral hemorrhage." | 5.41 | Effect of Intravenous Tranexamic Acid on Intracerebral Brain Hemorrhage in Traumatic Brain Injury. ( Farrahi, P; Marandi, HJ; Rasras, S; Safari, H; Zeinali, M, 2021) |
| " The antifibrinolytic drug tranexamic acid (TXA) improves survival in adults with traumatic hemorrhage, however, the drug has not been evaluated in a clinical trial in severely injured children." | 5.27 | Traumatic injury clinical trial evaluating tranexamic acid in children (TIC-TOC): study protocol for a pilot randomized controlled trial. ( Adelson, PD; Barnhard, SE; Bobinski, M; Ghetti, S; Hewes, HA; Holmes, JF; Kuppermann, N; Michael Dean, J; Myers, SR; Nishijima, DK; Roberts, I; Schalick, WO; Stanley, RM; Tran, NK; Tzimenatos, LS; VanBuren, J, 2018) |
| "Tranexamic acid is widely available and used off-label in patients with bleeding traumatic injury, although the literature does not consistently agree on its efficacy and safety." | 5.22 | Association of Tranexamic Acid Administration With Mortality and Thromboembolic Events in Patients With Traumatic Injury: A Systematic Review and Meta-analysis. ( Hess, S; Karl, V; Maegele, M; Mathes, T; Thorn, S, 2022) |
| "Tranexamic acid (TXA) is one of the measures indicated to reduce bleeding and the need for volume replacement." | 5.12 | Tranexamic acid in Neurosurgery: a controversy indication-review. ( Costa E Silva, LT; da Silva Brito, J; de Faria, JL; de Souza, NB; Figueiredo, EG; Kilesse, CTSM; Pereira, CU; Rabelo, NN, 2021) |
| "2020 has seen the birth of several relevant studies in emergency medicine of which the following is a selection : 1) conservative treatment for primary spontaneous pneumothorax may be offered ; 2) tranexamic acid does not provide benefit in gastrointestinal bleeding ; 3) the Canadian Syncope Risk Score is validated for the risk stratification of syncopal patients ; 4) early administration of tranexamic acid does not have a significant effect on the neurological prognosis of patients with moderate to severe trauma brain injury ; 5) the notion of frailty seems to be predictive of mortality in the event of intra-hospital cardiac arrest in elderly patients ; 6) a pharmacological cardioversion strategy followed by electrical cardioversion is as effective as initial electrical cardioversion for atrial fibrillation in the emergency room." | 5.12 | [Emergency medicine : update 2020]. ( Chevallier, JL; Darioli, V; Fehlmann, CA; Garcin, S; Gartner, B; Rojas Lazo, R, 2021) |
| "Several studies have demonstrated the clinical utility of tranexamic acid (TXA) for use in trauma patients presenting with significant hemorrhage." | 4.31 | EFFECTS OF TRANEXAMIC ACID ON NEUROPATHOLOGY, ELECTROENCEPHALOGRAPHY, AND CEREBRAL FIBRIN DEPOSITION IN A RAT MODEL OF POLYTRAUMA WITH CONCOMITANT PENETRATING TRAUMATIC BRAIN INJURY. ( Bailey, ZS; Cao, Y; Cardiff, K; Gilsdorf, J; Houchins, M; Lu, XC; Scultetus, A; Shear, D; Wang, P; Yang, X, 2023) |
| "Tranexamic acid (TXA) has shown to be beneficial in selected patients with hemorrhagic shock." | 4.12 | The effect of prehospital tranexamic acid on outcome in polytrauma patients with associated severe brain injury. ( Jochems, D; Leenen, LPH; van Wessem, KJP, 2022) |
| " Tranexamic acid (TXA) reduces the proteolytic action of plasmin on fibrin clots, resulting in an inhibition of fibrinolysis and stabilisation of established blood clots." | 4.12 | The role of tranexamic acid in traumatic brain injury. ( Ho, KM; Honeybul, S; Rosenfeld, JV, 2022) |
| "Tranexamic acid (TXA) is an antifibrinolytic that has shown some promise in improving outcomes in traumatic brain injury (TBI), but only when given early after injury." | 3.30 | The effects of timing of prehospital tranexamic acid on outcomes after traumatic brain injury: Subanalysis of a randomized controlled trial. ( Brito, AMP; El Haddi, J; Meier, EN; Rowell, SE; Schreiber, MA, 2023) |
| " This study investigates whether out-of-hospital TXA use is associated with adverse events or unfavorable outcomes in suspected traumatic brain injury (TBI) when intracranial hemorrhage (ICH) is absent on initial computed tomography." | 3.11 | Tranexamic acid is not inferior to placebo with respect to adverse events in suspected traumatic brain injury patients not in shock with a normal head computed tomography scan: A retrospective study of a randomized trial. ( Dewey, EN; Harmer, JW; Meier, EN; Rowell, SE; Schreiber, MA, 2022) |
| "Early identification of traumatic intracranial hemorrhage (ICH) has implications for triage and intervention." | 2.94 | Blood-based biomarkers for prediction of intracranial hemorrhage and outcome in patients with moderate or severe traumatic brain injury. ( Anderson, TN; Hinson, HE; Hwang, J; Munar, M; Papa, L; Rowell, SE; Vaughan, A, 2020) |
| "Tranexamic acid was highly cost-effective for patients with mild TBI and intracranial bleeding or patients with moderate TBI, at £4288 per QALY in the UK, and US$24 per QALY in Pakistan." | 2.94 | Cost-effectiveness analysis of tranexamic acid for the treatment of traumatic brain injury, based on the results of the CRASH-3 randomised trial: a decision modelling approach. ( Chaudhri, R; Lecky, FE; Miners, A; Roberts, I; Shakur-Still, H; Williams, J, 2020) |
| "While D-dimer and PAP levels reflect a lower degree of fibrinolysis following prehospital administration of TXA when compared with placebo in a large prehospital trial of patients with TBI, TEG obtained on admission and 6 hours later did not demonstrate any differences in fibrinolysis between the two TXA dosing regimens and placebo." | 2.94 | Tranexamic acid administration in the field does not affect admission thromboelastography after traumatic brain injury. ( Aufderheide, TP; Callum, J; Dewey, E; Dixon, AL; Dries, DJ; Farrell, DH; Frascone, RJ; Gandhi, RR; Garrett, JS; Jui, J; Kannas, D; McCully, BH; McMullan, J; Morrison, LJ; Rick, EA; Robinson, BRH; Rowell, SE; Schreiber, MA; Tallon, JM; Tibbs, B; Wade, CE; Weisfeldt, ML; Williams, C, 2020) |
| "However, pulmonary embolism was statistically more frequent in 'TXA' group (11." | 2.90 | Benefits of the tranexamic acid in head trauma with no extracranial bleeding: a prospective follow-up of 180 patients. ( Bouaziz, M; Chakroun-Walha, O; Chtara, K; Jerbi, M; Kanoun, H; Ksibi, H; Nasri, A; Rekik, N; Samet, A; Souissi, B; Talbi, A, 2019) |
| " Risks of adverse events (all moderate, low, or very low certainty) were similar between placebo and TXA." | 2.72 | Efficacy and safety of tranexamic acid in acute traumatic brain injury: a systematic review and meta-analysis of randomized-controlled trials. ( Alhazzani, W; Belley-Cote, EP; Fernando, SM; Lawati, KA; Maqbali, SA; Morgenstern, J; Owen, JJ; Petrosoniak, A; Quinlan, D; Rimawi, HA; Rochwerg, B; Sharif, S; Sharma, SV; Zeller, M, 2021) |
| "Tranexamic acid shows some treatment efficacy for traumatic brain injury." | 2.66 | The efficacy of tranexamic acid for brain injury: A meta-analysis of randomized controlled trials. ( Chen, H; Chen, M, 2020) |
| "Tranexamic acid (TXA) has a time tested role in preventing poor outcomes linked to excessive haemorrhage in trauma patients." | 2.66 | Early tranexamic acid in traumatic brain injury: Evidence for an effective therapy. ( Bukhari, NS; Jooma, R, 2020) |
| "Mice were then subjected to controlled hemorrhagic shock for 1 h to a goal MAP of 25 mmHg." | 1.72 | MULTIMODAL TREATMENT APPROACHES TO COMBINED TRAUMATIC BRAIN INJURY AND HEMORRHAGIC SHOCK ALTER POSTINJURY INFLAMMATORY RESPONSE. ( Baucom, MR; England, LG; Goodman, MD; Pritts, TA; Schuster, RM; Wallen, TE, 2022) |
| "The results of a test of the total thrombus-formation analysis system showed improved blood clot formation ability." | 1.56 | Effect of Tranexamic Acid for Traumatic Brain Injury: A Case Report. ( Inoue, S; Miike, T; Sakamoto, Y, 2020) |
| "Tranexamic acid (TXA) is an anti-fibrinolytic agent used to reduce bleeding in various conditions including traumatic brain injury (TBI)." | 1.56 | Sex-dependent effects of tranexamic acid on blood-brain barrier permeability and the immune response following traumatic brain injury in mice. ( Daglas, M; Draxler, DF; Galle, A; Ho, H; Liu, Z; Medcalf, RL; Sashindranath, M, 2020) |
| " We aimed to measure plasma levels of tranexamic acid in patients receiving pre-hospital anti-hyperfibrinolytic therapy and to build a population pharmacokinetic model to propose an optimised dosing regimen." | 1.48 | Optimisation of the dosage of tranexamic acid in trauma patients with population pharmacokinetic analysis. ( Albrecht, R; Grassin-Delyle, S; Mueller, S; Spahn, DR; Stein, P; Theusinger, OM; Urien, S, 2018) |
| "Tranexamic acid (TXA) has been shown clinically to reduce mortality in hemorrhaging and head-injured trauma patients and has the potential to mitigate secondary brain injury with its reported antifibrinolytic and antiinflammatory properties." | 1.46 | Impact of tranexamic acid on coagulation and inflammation in murine models of traumatic brain injury and hemorrhage. ( Boudreau, RM; Caldwell, CC; Friend, LA; Goetzman, H; Goodman, MD; Johnson, M; Makley, AT; Pritts, TA; Veile, R, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (21.43) | 24.3611 |
| 2020's | 55 (78.57) | 2.80 |
| Authors | Studies |
|---|---|
| Maegele, M | 3 |
| van Wessem, KJP | 1 |
| Jochems, D | 1 |
| Leenen, LPH | 1 |
| Wu, B | 1 |
| Lu, Y | 1 |
| Yu, Y | 1 |
| Yue, H | 1 |
| Wang, J | 1 |
| Chong, Y | 1 |
| Cui, W | 1 |
| Honeybul, S | 1 |
| Ho, KM | 1 |
| Rosenfeld, JV | 1 |
| Karl, V | 1 |
| Thorn, S | 1 |
| Mathes, T | 1 |
| Hess, S | 1 |
| Wallen, TE | 3 |
| Singer, KE | 2 |
| Baucom, MR | 3 |
| England, LG | 2 |
| Schuster, RM | 3 |
| Pritts, TA | 3 |
| Goodman, MD | 4 |
| Harmer, JW | 1 |
| Dewey, EN | 1 |
| Meier, EN | 3 |
| Rowell, SE | 7 |
| Schreiber, MA | 4 |
| Youngs, J | 1 |
| Blakeman, TC | 1 |
| McGuire, JL | 1 |
| Strilka, R | 1 |
| Schober, P | 3 |
| Loer, SA | 3 |
| Schwarte, LA | 3 |
| Brito, AMP | 1 |
| El Haddi, J | 1 |
| Chang, WJ | 1 |
| Ho, MP | 1 |
| Biffi, A | 2 |
| Porcu, G | 2 |
| Castellini, G | 2 |
| Napoletano, A | 2 |
| Coclite, D | 2 |
| D'Angelo, D | 2 |
| Fauci, AJ | 2 |
| Iacorossi, L | 2 |
| Latina, R | 2 |
| Salomone, K | 2 |
| Iannone, P | 2 |
| Gianola, S | 2 |
| Chiara, O | 2 |
| Xiong, Y | 1 |
| Guo, X | 1 |
| Huang, X | 1 |
| Kang, X | 1 |
| Zhou, J | 1 |
| Chen, C | 1 |
| Pan, Z | 1 |
| Wang, L | 1 |
| Goldbrunner, R | 1 |
| Stavrinou, L | 1 |
| Stavrinou, P | 1 |
| Lin, S | 1 |
| Chen, Y | 1 |
| Hu, W | 1 |
| Zheng, F | 1 |
| Culkin, MC | 1 |
| Bele, P | 1 |
| Georges, AP | 1 |
| Lopez, AJ | 1 |
| Niziolek, G | 1 |
| Jacovides, CL | 1 |
| Song, H | 1 |
| Johnson, VE | 1 |
| Kaplan, LJ | 1 |
| Smith, DH | 1 |
| Pascual, JL | 1 |
| Bailey, ZS | 1 |
| Yang, X | 1 |
| Cardiff, K | 1 |
| Wang, P | 1 |
| Houchins, M | 1 |
| Lu, XC | 1 |
| Cao, Y | 1 |
| Gilsdorf, J | 1 |
| Scultetus, A | 1 |
| Shear, D | 1 |
| Sigmon, J | 1 |
| Crowley, KL | 1 |
| Groth, CM | 1 |
| McKinley, WI | 1 |
| Mansour, A | 1 |
| Hoefer, L | 1 |
| Polcari, A | 1 |
| Schreiber, M | 1 |
| Benjamin, AJ | 1 |
| Tanaka, T | 1 |
| Suehiro, E | 1 |
| Matsuno, A | 1 |
| Draxler, DF | 3 |
| Daglas, M | 3 |
| Fernando, A | 1 |
| Hanafi, G | 2 |
| McCutcheon, F | 1 |
| Ho, H | 3 |
| Galle, A | 3 |
| Gregory, J | 1 |
| Larsson, P | 1 |
| Keragala, C | 2 |
| Wright, DK | 1 |
| Tavancheh, E | 1 |
| Au, AE | 1 |
| Niego, B | 1 |
| Wilson, K | 1 |
| Plebanski, M | 1 |
| Sashindranath, M | 3 |
| Medcalf, RL | 3 |
| Cap, AP | 1 |
| Chen, H | 1 |
| Chen, M | 1 |
| Taccone, FS | 1 |
| Citerio, G | 2 |
| Stocchetti, N | 1 |
| Fishman, J | 1 |
| Hussain, M | 1 |
| Fisher, E | 1 |
| Bukhari, NS | 1 |
| Jooma, R | 1 |
| Cook, R | 1 |
| Lyon-Maris, J | 1 |
| Martin, R | 1 |
| Blanchard, PG | 1 |
| Paré, D | 1 |
| Truchot, J | 1 |
| Mercier, E | 1 |
| Anderson, TN | 2 |
| Hwang, J | 2 |
| Munar, M | 1 |
| Papa, L | 1 |
| Hinson, HE | 1 |
| Vaughan, A | 1 |
| July, J | 1 |
| Pranata, R | 1 |
| Baron, T | 1 |
| Novak, A | 1 |
| Miike, T | 1 |
| Sakamoto, Y | 1 |
| Inoue, S | 1 |
| de Faria, JL | 1 |
| da Silva Brito, J | 1 |
| Costa E Silva, LT | 1 |
| Kilesse, CTSM | 1 |
| de Souza, NB | 1 |
| Pereira, CU | 1 |
| Figueiredo, EG | 1 |
| Rabelo, NN | 1 |
| Fletcher-Sandersjöö, A | 1 |
| Thelin, EP | 1 |
| Svensson, M | 1 |
| Bellander, BM | 1 |
| Liu, Z | 1 |
| Solla, DJF | 1 |
| Rubiano, AM | 1 |
| Teixeira, MJ | 1 |
| de Andrade, AF | 1 |
| Paiva, WS | 1 |
| Reynard, C | 1 |
| Berg, PVD | 1 |
| Body, R | 1 |
| Kolias, AG | 1 |
| Horner, D | 1 |
| Menon, DK | 1 |
| Wilson, M | 2 |
| Hutchinson, PJ | 1 |
| Bourn, S | 1 |
| Dodds, N | 1 |
| Mascha, EJ | 1 |
| Bossers, SM | 2 |
| Roberts, I | 6 |
| Shakur-Still, H | 4 |
| Goursaud, S | 1 |
| Gaberel, T | 1 |
| Mansukhani, R | 1 |
| Frimley, L | 1 |
| Sharples, L | 1 |
| Williams, J | 1 |
| Lecky, FE | 1 |
| Chaudhri, R | 1 |
| Miners, A | 1 |
| Cone, DC | 1 |
| Spaite, DW | 1 |
| Coats, TJ | 1 |
| McKnight, B | 1 |
| Kannas, D | 2 |
| May, S | 1 |
| Sheehan, K | 1 |
| Bulger, EM | 1 |
| Idris, AH | 1 |
| Christenson, J | 1 |
| Morrison, LJ | 2 |
| Frascone, RJ | 2 |
| Bosarge, PL | 2 |
| Colella, MR | 1 |
| Johannigman, J | 1 |
| Cotton, BA | 1 |
| Callum, J | 2 |
| McMullan, J | 2 |
| Dries, DJ | 2 |
| Tibbs, B | 2 |
| Richmond, NJ | 1 |
| Weisfeldt, ML | 2 |
| Tallon, JM | 2 |
| Garrett, JS | 2 |
| Zielinski, MD | 1 |
| Aufderheide, TP | 2 |
| Gandhi, RR | 2 |
| Schlamp, R | 1 |
| Robinson, BRH | 2 |
| Jui, J | 2 |
| Klein, L | 1 |
| Rizoli, S | 1 |
| Gamber, M | 1 |
| Fleming, M | 1 |
| Vincent, LE | 1 |
| Williams, C | 3 |
| Hendrickson, A | 1 |
| Simonson, R | 1 |
| Klotz, P | 1 |
| Sopko, G | 1 |
| Witham, W | 1 |
| Ferrara, M | 1 |
| Rostami, E | 1 |
| Kongstad, P | 1 |
| Marklund, N | 1 |
| Lawati, KA | 1 |
| Sharif, S | 1 |
| Maqbali, SA | 1 |
| Rimawi, HA | 1 |
| Petrosoniak, A | 1 |
| Belley-Cote, EP | 1 |
| Sharma, SV | 1 |
| Morgenstern, J | 1 |
| Fernando, SM | 1 |
| Owen, JJ | 1 |
| Zeller, M | 1 |
| Quinlan, D | 1 |
| Alhazzani, W | 1 |
| Rochwerg, B | 1 |
| Dixon, AL | 1 |
| McCully, BH | 1 |
| Rick, EA | 1 |
| Dewey, E | 1 |
| Farrell, DH | 2 |
| Wade, CE | 1 |
| Long, B | 1 |
| Gottlieb, M | 1 |
| Maas, AIR | 1 |
| Steyerberg, EW | 1 |
| Nelson Yap, KB | 1 |
| Albert Wong, SH | 1 |
| Idris, Z | 1 |
| Sanford, K | 1 |
| Garcia, S | 1 |
| Mahmood, A | 2 |
| Needham, K | 1 |
| Harris, T | 1 |
| Jamaluddin, SF | 1 |
| Davies, D | 1 |
| Belli, A | 1 |
| Mohamed, FL | 1 |
| Leech, C | 1 |
| Lotfi, HM | 1 |
| Moss, P | 1 |
| Lecky, F | 1 |
| Hopkins, P | 1 |
| Wong, D | 1 |
| Boyle, A | 1 |
| Darwent, M | 1 |
| Bloemers, FW | 1 |
| Den Hartog, D | 1 |
| Van Lieshout, EMM | 1 |
| Hoogerwerf, N | 1 |
| van der Naalt, J | 1 |
| Absalom, AR | 1 |
| Peerdeman, SM | 1 |
| Boer, C | 1 |
| Chevallier, JL | 1 |
| Rojas Lazo, R | 1 |
| Gartner, B | 1 |
| Garcin, S | 1 |
| Fehlmann, CA | 1 |
| Darioli, V | 1 |
| Safari, H | 1 |
| Farrahi, P | 1 |
| Rasras, S | 1 |
| Marandi, HJ | 1 |
| Zeinali, M | 1 |
| Boudreau, RM | 1 |
| Johnson, M | 1 |
| Veile, R | 1 |
| Friend, LA | 1 |
| Goetzman, H | 1 |
| Caldwell, CC | 1 |
| Makley, AT | 1 |
| Shakur, H | 1 |
| Fakharian, E | 1 |
| Abedzadeh-Kalahroudi, M | 1 |
| Atoof, F | 1 |
| Grassin-Delyle, S | 1 |
| Theusinger, OM | 1 |
| Albrecht, R | 1 |
| Mueller, S | 1 |
| Spahn, DR | 1 |
| Urien, S | 1 |
| Stein, P | 1 |
| Chakroun-Walha, O | 1 |
| Samet, A | 1 |
| Jerbi, M | 1 |
| Nasri, A | 1 |
| Talbi, A | 1 |
| Kanoun, H | 1 |
| Souissi, B | 1 |
| Chtara, K | 1 |
| Bouaziz, M | 1 |
| Ksibi, H | 1 |
| Rekik, N | 1 |
| Nishijima, DK | 1 |
| VanBuren, J | 1 |
| Hewes, HA | 1 |
| Myers, SR | 1 |
| Stanley, RM | 1 |
| Adelson, PD | 1 |
| Barnhard, SE | 1 |
| Bobinski, M | 1 |
| Ghetti, S | 1 |
| Holmes, JF | 1 |
| Schalick, WO | 1 |
| Tran, NK | 1 |
| Tzimenatos, LS | 1 |
| Michael Dean, J | 1 |
| Kuppermann, N | 1 |
| Weng, S | 1 |
| Wang, W | 1 |
| Wei, Q | 1 |
| Lan, H | 1 |
| Su, J | 1 |
| Xu, Y | 1 |
| Wiegele, M | 1 |
| Schöchl, H | 1 |
| Haushofer, A | 1 |
| Ortler, M | 1 |
| Leitgeb, J | 1 |
| Kwasny, O | 1 |
| Beer, R | 1 |
| Ay, C | 1 |
| Schaden, E | 1 |
| Awad, MM | 1 |
| Roquilly, A | 1 |
| Lyras, D | 1 |
| Stephens, SW | 1 |
| Gray, R | 1 |
| Kerby, JD | 1 |
| Wang, HE | 1 |
| Jokar, A | 1 |
| Ahmadi, K | 1 |
| Salehi, T | 1 |
| Sharif-Alhoseini, M | 1 |
| Rahimi-Movaghar, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prehospital Tranexamic Acid Use for Traumatic Brain Injury[NCT01990768] | Phase 2 | 967 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| Tranexamic Acid for the Treatment of Significant Traumatic Brain Injury: an International Randomised, Double Blind Placebo Controlled Trial[NCT01402882] | Phase 3 | 12,737 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma[NCT05713630] | Phase 3 | 130 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): A Pilot and Feasibility Study[NCT02840097] | Phase 2 | 31 participants (Actual) | Interventional | 2019-03-04 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The DRS is designed to classify patients based on their degree of function after brain injury. The DRS consists of 8 items that fall into 4 categories: (a) arousability, awareness and responsivity, (b) cognitive ability for self-care activities, (c) dependence on others, and (d) psychosocial adaptability. The score ranges from 0 (no disability) to 30 (death). (NCT01990768)
Timeframe: 6 months post-injury
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 8.0 |
| Bolus-Maintenance | 8.1 |
| Bolus Only | 6.6 |
The DRS is designed to classify patients based on their degree of function after brain injury. The DRS consists of 8 items that fall into 4 categories: (a) arousability, awareness and responsivity, (b) cognitive ability for self-care activities, (c) dependence on others, and (d) psychosocial adaptability. The score ranges from 0 (no disability) to 30 (death). (NCT01990768)
Timeframe: At the end of the hospital stay (average of 9 days post injury)
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 9.0 |
| Bolus-Maintenance | 9.4 |
| Bolus Only | 8.1 |
Hospital-free days count any day from hospital admission through day 28 that the patient is alive and out of the hospital. (NCT01990768)
Timeframe: From hospital admission through day 28
| Intervention | days (Mean) |
|---|---|
| Placebo | 13.6 |
| Bolus-Maintenance | 13.6 |
| Bolus Only | 14.1 |
ICU-free days count any day from hospital admission through day 28 that the patient is alive and not in the ICU. Subjects who die prior to discharge (even if after 28 days) are assigned a value of 0. (NCT01990768)
Timeframe: From hospital admission through day 28
| Intervention | days (Mean) |
|---|---|
| Placebo | 18.5 |
| Bolus-Maintenance | 18.1 |
| Bolus Only | 19.1 |
The counts of patients who died on or before day 28 are reported. (NCT01990768)
Timeframe: 28 days after hospital arrival
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 50 |
| Bolus-Maintenance | 53 |
| Bolus Only | 40 |
Diagnosis of one or more of the following: cerebral ischemic event, myocardial infarction (MI), deep vein thrombosis (DVT), pulmonary embolism (PE), or any other thromboembolic event (NCT01990768)
Timeframe: From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 30 |
| Bolus-Maintenance | 13 |
| Bolus Only | 31 |
Diagnosis of cerebral ischemic event (NCT01990768)
Timeframe: From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 10 |
| Bolus-Maintenance | 3 |
| Bolus Only | 13 |
Diagnosis of DVT (NCT01990768)
Timeframe: From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 9 |
| Bolus-Maintenance | 3 |
| Bolus Only | 10 |
All clinically indicated head computed tomography (CT) scans obtained during the initial hospitalization or within the first 28 days were assessed for ICH. Parenchymal (IPH), subdural (SDH) and epidural (EDH) hemorrhage volumes were measured and quantified using volumetric software and verified by manual calculations based on the previously validated ABC/2 technique. The sum of the IPH, SDH, and EDH volumes were compared across scans. A relative increase of 33% (and at least a 1 ml increase) on any subsequent scan compared to the initial scan was defined as a progression. (NCT01990768)
Timeframe: From hospital admission through 28 days or the end of the hospital stay if sooner (average of 13 days among patients with multiple scans)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 30 |
| Bolus-Maintenance | 26 |
| Bolus Only | 27 |
Diagnosis of an acute myocardial infarction (NCT01990768)
Timeframe: From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 1 |
| Bolus-Maintenance | 3 |
| Bolus Only | 2 |
Neurosurgical interventions include craniotomy, craniectomy, and placement of a neuromonitoring or drainage device. Counts are of subjects with one or more neurosurgical interventions. (NCT01990768)
Timeframe: From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 54 |
| Bolus-Maintenance | 62 |
| Bolus Only | 75 |
Diagnosis of PE (NCT01990768)
Timeframe: From hospital admission through 28 days or the end of the hospital stay if sooner (average of 9 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 5 |
| Bolus-Maintenance | 3 |
| Bolus Only | 6 |
Seizures may cause involuntary changes in body movement or function, sensation, awareness, or behavior. Seizures are often associated with a sudden and involuntary contraction of a group of muscles and loss of consciousness. Seizures or episodes of seizure-like activity were reported by medics in the field following the start of study drug infusion through hand-off to the trauma center and by trauma center staff through discharge. Reported events were included if providers gave anti-seizure medication and/or the event was confirmed by EEG. (NCT01990768)
Timeframe: From start of study drug infusion through 28 days or the end of the hospital stay if sooner (average of 9 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 7 |
| Bolus-Maintenance | 5 |
| Bolus Only | 17 |
GOS-E subdivides the categories of severe and moderate disability and good recovery using a scale of 1 to 8 where 1 = death, 2 = vegetative state, 3 = lower severe disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper moderate disability, 7 = lower good recovery, and 8 = upper good recovery. Structured telephone interviews have been developed and validated for the GOS-E and these questions were incorporated into the follow-up survey. GOS-E was dichotomized into unfavorable (1 to 4) and favorable (5 to 8) outcomes. The number of subjects with unfavorable outcome is reported. (NCT01990768)
Timeframe: At the end of the hospital stay (average of 9 days post injury)
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 196 |
| Bolus-Maintenance | 193 |
| Bolus Only | 228 |
Ventilator-free days count any day from hospital admission through day 28 that the patient is alive and does not require mechanical ventilatory support. Subjects who die prior to discharge (even if after 28 days) are assigned a value of 0. (NCT01990768)
Timeframe: From hospital admission through day 28
| Intervention | days (Mean) |
|---|---|
| Placebo | 20.2 |
| Bolus-Maintenance | 19.9 |
| Bolus Only | 20.9 |
Total volume of packed red blood cells, platelets, fresh frozen plasma, and cryoprecipitate (NCT02840097)
Timeframe: First 48 hours after randomization
| Intervention | ml (Mean) |
|---|---|
| Tranexamic Acid Dose A | 367.4 |
| Tranexamic Acid Dose B | 150.4 |
| Placebo | 303.6 |
Intracranial hemorrhage progression on cranial computed tomography (CT) imaging; hemorrhage will be measured using the ABC/2 volume estimation and relative to the total brain volume (calculated by the XYZ/2 volume estimation); more intracranial hemorrhage progression represents a worse outcome. Change is calculated as the difference between the baseline and repeat cranial CT imaging. The repeat CT is conducted 24 hours (±6 hours) after the baseline CT. (NCT02840097)
Timeframe: 24 hours (±6 hours)
| Intervention | Proportional change (Mean) |
|---|---|
| Tranexamic Acid Dose A | 0.003 |
| Tranexamic Acid Dose B | 0.001 |
| Placebo | 0.003 |
Any non-cerebral venous or arterial thrombosis on standard diagnostic imaging post-randomization (NCT02840097)
Timeframe: Day 7 of hospitalization or hospital discharge (whichever comes first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Dose A | 0 |
| Tranexamic Acid Dose B | 0 |
| Placebo | 0 |
Clinical or electroencephalogram-documented (NCT02840097)
Timeframe: 24 hours after receiving drug
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Dose A | 0 |
| Tranexamic Acid Dose B | 0 |
| Placebo | 1 |
Neurocognitive functioning and quality-of-life measures; range from 0 to 100 quality of life units with higher scores representing better outcomes. Measurements occur at 1 week, 1 month, 3 months, and 6 months to generate an area under the curve of quality of life units. (NCT02840097)
Timeframe: 6 months
| Intervention | Quality of life units * months (Mean) |
|---|---|
| Tranexamic Acid Dose A | 64.9 |
| Tranexamic Acid Dose B | 60.2 |
| Placebo | 67.2 |
Test of working memory; higher scores represent a better outcome, range from 0 to infinity (NCT02840097)
Timeframe: 1 week, 1 month, 3 months, and 6 months
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total forward digit span, 1 week | Total backward digit span, 1 week | Total forward digit span, 1 month | Total backward digit span, 1 month | Total forward digit span, 3 months | Total backward digit span, 3 months | Total forward digit span, 6 months | Total backward digit span, 6 months | |
| Placebo | 8.8 | 7.3 | 7.5 | 5.3 | 8.6 | 6.5 | 8.4 | 5.8 |
| Tranexamic Acid Dose A | 8.4 | 6.0 | 7.2 | 6.2 | 9.1 | 8.7 | 11.7 | 10.4 |
| Tranexamic Acid Dose B | 8.4 | 6.0 | 7.9 | 6.2 | 10.4 | 7.8 | 10.0 | 6.0 |
Global functioning; range is 1 to 8 with higher scores representing better outcomes; 1=death, 2=vegetative state, 3=lower severe disability, 4=upper severe disability, 5=lower moderate disability, 6=upper moderate disability, 7=lower good recovery, 8=upper good recovery (NCT02840097)
Timeframe: 1 week, 1 month, 3 months, and 6 months
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| 1 week | 1 month | 3 months | 6 months | |
| Placebo | 5.3 | 4.5 | 4.2 | 4.3 |
| Tranexamic Acid Dose A | 4.6 | 4.9 | 3.8 | 3.7 |
| Tranexamic Acid Dose B | 5.2 | 5.1 | 4.6 | 2.9 |
Neurocognitive functioning and quality-of-life measures; range from 0 to 100 with higher scores representing better outcomes (NCT02840097)
Timeframe: 1 week, 1 month, 3 months, and 6 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 1 week | 1 month | 3 months | 6 months | |
| Placebo | 57.9 | 60.5 | 68.9 | 68.9 |
| Tranexamic Acid Dose A | 43.7 | 57.0 | 77.3 | 81.6 |
| Tranexamic Acid Dose B | 52.4 | 61.5 | 77.5 | 84.3 |
14 reviews available for tranexamic acid and Brain Injuries, Traumatic
| Article | Year |
|---|---|
Prehospital Tranexamic Acid (TXA) in Patients with Traumatic Brain Injury (TBI).
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Emergency Medical Services; Humans; Multicenter | 2021 |
Association of Tranexamic Acid Administration With Mortality and Thromboembolic Events in Patients With Traumatic Injury: A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Hemorrhage; Humans; Thromboembolism; Tranexamic | 2022 |
Antifibrinolytics in the treatment of traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Hemorrhage; Humans; Tranexamic Acid | 2022 |
Systemic hemostatic agents initiated in trauma patients in the pre-hospital setting: a systematic review.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Hemorrhage; Hemostatics; Humans; Quality of Life | 2023 |
Systemic hemostatic agents initiated in trauma patients in the pre-hospital setting: a systematic review.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Hemorrhage; Hemostatics; Humans; Quality of Life | 2023 |
Systemic hemostatic agents initiated in trauma patients in the pre-hospital setting: a systematic review.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Hemorrhage; Hemostatics; Humans; Quality of Life | 2023 |
Systemic hemostatic agents initiated in trauma patients in the pre-hospital setting: a systematic review.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Hemorrhage; Hemostatics; Humans; Quality of Life | 2023 |
Efficacy and safety of tranexamic acid in intracranial haemorrhage: A meta-analysis.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Humans; Hydrocephalus; Quality of Life; Subarach | 2023 |
The efficacy of tranexamic acid for brain injury: A meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Cerebral Hemorrhage; Humans; Randomized Controll | 2020 |
Early tranexamic acid in traumatic brain injury: Evidence for an effective therapy.
Topics: Antifibrinolytic Agents; Brain Contusion; Brain Hemorrhage, Traumatic; Brain Injuries, Traumatic; Di | 2020 |
Tranexamic acid is associated with reduced mortality, hemorrhagic expansion, and vascular occlusive events in traumatic brain injury - meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Hemorrhage; Humans; Randomized Controlled Trials | 2020 |
Tranexamic acid in Neurosurgery: a controversy indication-review.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Brain Injuries, Traumatic; | 2021 |
Time Course of Hemostatic Disruptions After Traumatic Brain Injury: A Systematic Review of the Literature.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Brain Injuries, Traumatic; Hemostatics; Humans | 2021 |
Efficacy and safety of tranexamic acid in acute traumatic brain injury: a systematic review and meta-analysis of randomized-controlled trials.
Topics: Adolescent; Adult; Brain Injuries; Brain Injuries, Traumatic; Humans; Randomized Controlled Trials a | 2021 |
[Emergency medicine : update 2020].
Topics: Aged; Atrial Fibrillation; Brain Injuries, Traumatic; Canada; Electric Countershock; Emergency Medic | 2021 |
Fibrinolysis in Traumatic Brain Injury: Diagnosis, Management, and Clinical Considerations.
Topics: Blood Coagulation; Blood Coagulation Disorders; Brain Injuries, Traumatic; Fibrinolysis; Humans; Tra | 2021 |
Effect of Tranexamic Acid in Patients with Traumatic Brain Injury: A Systematic Review and Meta-Analysis.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Humans; Tranexamic Acid | 2019 |
18 trials available for tranexamic acid and Brain Injuries, Traumatic
| Article | Year |
|---|---|
Effect of tranexamic acid on the prognosis of patients with traumatic brain injury undergoing craniotomy: study protocol for a randomised controlled trial.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Craniotomy; Humans; Prognosis; Randomized Contro | 2021 |
Tranexamic acid is not inferior to placebo with respect to adverse events in suspected traumatic brain injury patients not in shock with a normal head computed tomography scan: A retrospective study of a randomized trial.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Humans; Retrospective Studies; Shock; Tomography | 2022 |
The effects of timing of prehospital tranexamic acid on outcomes after traumatic brain injury: Subanalysis of a randomized controlled trial.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Emergency Medical Services; Glasgow Coma Scale; | 2023 |
Therapeutic review: The role of tranexamic acid in management of traumatic brain injury, nontraumatic intracranial hemorrhage, and aneurysmal subarachnoid hemorrhage.
Topics: Brain Injuries; Brain Injuries, Traumatic; Craniocerebral Trauma; Humans; Intracranial Hemorrhages; | 2023 |
Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial.
Topics: Adult; Aged; Antifibrinolytic Agents; Brain Injuries, Traumatic; Drug Administration Schedule; Femal | 2019 |
Tranexamic acid in ENT.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Brain Injuries, Traumatic; Humans; Otolaryngology; Pl | 2019 |
Tranexamic acid in traumatic brain injury: an explanatory study nested within the CRASH-3 trial.
Topics: Adult; Antifibrinolytic Agents; Brain Injuries, Traumatic; Cerebral Hemorrhage; Female; Glasgow Coma | 2021 |
Blood-based biomarkers for prediction of intracranial hemorrhage and outcome in patients with moderate or severe traumatic brain injury.
Topics: Adult; Antifibrinolytic Agents; Biomarkers; Brain Injuries, Traumatic; Double-Blind Method; Emergenc | 2020 |
Accuracy of time to treatment estimates in the CRASH-3 clinical trial: impact on the trial results.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Bayes Theorem; Brain Injuries, Traumatic; Child; Child, | 2020 |
Cost-effectiveness analysis of tranexamic acid for the treatment of traumatic brain injury, based on the results of the CRASH-3 randomised trial: a decision modelling approach.
Topics: Brain Injuries, Traumatic; Cost-Benefit Analysis; Decision Support Techniques; Humans; Pakistan; Qua | 2020 |
Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury.
Topics: Adult; Antifibrinolytic Agents; Brain Diseases; Brain Injuries, Traumatic; Double-Blind Method; Emer | 2020 |
Tranexamic acid administration in the field does not affect admission thromboelastography after traumatic brain injury.
Topics: Abbreviated Injury Scale; Adolescent; Adult; alpha-2-Antiplasmin; Antifibrinolytic Agents; Blood Coa | 2020 |
Effect of Intravenous Tranexamic Acid on Intracerebral Brain Hemorrhage in Traumatic Brain Injury.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Antifibrinolytic Agents; Brain Injuries, Traum | 2021 |
A nested mechanistic sub-study into the effect of tranexamic acid versus placebo on intracranial haemorrhage and cerebral ischaemia in isolated traumatic brain injury: study protocol for a randomised controlled trial (CRASH-3 Trial Intracranial Bleeding M
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Brain Ischemia; Clinical Protocols; Double-Blind | 2017 |
Effect of Tranexamic Acid on Prevention of Hemorrhagic Mass Growth in Patients with Traumatic Brain Injury.
Topics: Adult; Antifibrinolytic Agents; Brain Injuries, Traumatic; Double-Blind Method; Female; Follow-Up St | 2018 |
Benefits of the tranexamic acid in head trauma with no extracranial bleeding: a prospective follow-up of 180 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Component Transfusion; Br | 2019 |
Traumatic injury clinical trial evaluating tranexamic acid in children (TIC-TOC): study protocol for a pilot randomized controlled trial.
Topics: Adolescent; Antifibrinolytic Agents; Brain Injuries, Traumatic; Child; Child, Preschool; Clinical Tr | 2018 |
The effect of tranexamic acid in traumatic brain injury: A randomized controlled trial.
Topics: Adult; Antifibrinolytic Agents; Brain Injuries, Traumatic; Cerebral Hemorrhage, Traumatic; Female; H | 2017 |
38 other studies available for tranexamic acid and Brain Injuries, Traumatic
| Article | Year |
|---|---|
The effect of prehospital tranexamic acid on outcome in polytrauma patients with associated severe brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Female; Humans; Male; Middle Age | 2022 |
The role of tranexamic acid in traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Fibrinolysis; Humans; Thrombosis; Tranexamic Aci | 2022 |
Effects of antifibrinolytics on systemic and cerebral inflammation after traumatic brain injury.
Topics: Aminocaproic Acid; Animals; Antifibrinolytic Agents; Brain Injuries, Traumatic; Chemokine CCL2; Chem | 2022 |
Postinjury Treatment to Mitigate the Effects of Aeromedical Evacuation After Traumatic Brain Injury in a Porcine Model.
Topics: Air Ambulances; Allopurinol; Animals; Brain Injuries, Traumatic; Humans; Interleukin-6; Mice; Propra | 2022 |
Tranexamic acid for traumatic brain injury.
Topics: Brain Injuries, Traumatic; Humans; Tranexamic Acid | 2023 |
MULTIMODAL TREATMENT APPROACHES TO COMBINED TRAUMATIC BRAIN INJURY AND HEMORRHAGIC SHOCK ALTER POSTINJURY INFLAMMATORY RESPONSE.
Topics: Animals; Biomarkers; Brain Injuries; Brain Injuries, Traumatic; Chemokine CCL3; Combined Modality Th | 2022 |
Early posttraumatic brain injury tranexamic acid prevents blood-brain barrier hyperpermeability and improves surrogates of neuroclinical recovery.
Topics: Animals; Antifibrinolytic Agents; Blood-Brain Barrier; Brain Edema; Brain Injuries, Traumatic; Male; | 2023 |
EFFECTS OF TRANEXAMIC ACID ON NEUROPATHOLOGY, ELECTROENCEPHALOGRAPHY, AND CEREBRAL FIBRIN DEPOSITION IN A RAT MODEL OF POLYTRAUMA WITH CONCOMITANT PENETRATING TRAUMATIC BRAIN INJURY.
Topics: Animals; Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Electroencephalography; | 2023 |
Tranexamic Acid, Mortality, and Intracranial Hemorrhage Type in Moderate or Severe Traumatic Brain Injury.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Humans; Intracranial Hemorrhages; Tranexamic Aci | 2023 |
[Initial Management of Traumatic Brain Injury].
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Humans; Japan; Tranexamic Acid | 2023 |
Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis.
Topics: Animals; Antifibrinolytic Agents; Brain; Brain Injuries, Traumatic; Cell Proliferation; Chemotaxis, | 2019 |
CRASH-3: a win for patients with traumatic brain injury.
Topics: Brain Injuries; Brain Injuries, Traumatic; Humans; Morbidity; Tranexamic Acid | 2019 |
Is tranexamic acid going to CRASH the management of traumatic brain injury?
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Humans; Tranexamic Acid; Vascula | 2020 |
Tranexamic acid is safe to use following mild-to-moderate traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Humans; Technology Assessment, Biomedical; Trane | 2020 |
Does tranexamic acid reduce traumatic brain injury-related death?
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Humans; Tranexamic Acid | 2020 |
Tranexamic acid in acute traumatic brain injury.
Topics: Brain Injuries, Traumatic; Humans; Tranexamic Acid | 2021 |
Effect of Tranexamic Acid for Traumatic Brain Injury: A Case Report.
Topics: Aged, 80 and over; Antifibrinolytic Agents; Blood Coagulation; Blood Coagulation Disorders; Brain In | 2020 |
Sex-dependent effects of tranexamic acid on blood-brain barrier permeability and the immune response following traumatic brain injury in mice.
Topics: Animals; Antifibrinolytic Agents; Blood-Brain Barrier; Brain Injuries, Traumatic; Female; Immunity; | 2020 |
Tranexamic acid for traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Humans; Tranexamic Acid; Vascula | 2020 |
Tranexamic acid for traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Humans; Tranexamic Acid; Vascula | 2020 |
Tranexamic acid for traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Humans; Tranexamic Acid; Vascula | 2020 |
Tranexamic acid for traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Humans; Tranexamic Acid; Vascula | 2020 |
Tranexamic acid for traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Humans; Tranexamic Acid; Vascula | 2020 |
Tranexamic acid for traumatic brain injury - Authors' reply.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Humans; Tranexamic Acid | 2020 |
Tranexamic acid for traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Humans; Tranexamic Acid; Vascula | 2020 |
Out-of-Hospital Tranexamic Acid for Traumatic Brain Injury.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Humans; Tranexamic Acid | 2020 |
[Should all patients with traumatic brain injury receive tranexamic acid?]
Topics: Antifibrinolytic Agents; Brain Concussion; Brain Injuries, Traumatic; Double-Blind Method; Humans; R | 2020 |
Tranexamic Acid for Traumatic Brain Injury.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Humans; Tranexamic Acid | 2021 |
Tranexamic acid in traumatic brain injury: systematic review and meta-analysis trumps a large clinical trial?
Topics: Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Humans; Tranexamic Acid | 2021 |
Tranexamic acid in traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Humans; Prospective Studies; Thrombosis; Tranexa | 2020 |
Tranexamic acid and traumatic brain injuries.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Cerebral Hemorrhage; Female; Humans; Male; Rando | 2020 |
Effect of tranexamic acid on intracranial haemorrhage and infarction in patients with traumatic brain injury: a pre-planned substudy in a sample of CRASH-3 trial patients.
Topics: Adult; Antifibrinolytic Agents; Brain Injuries, Traumatic; Female; Humans; Infarction; Intracranial | 2021 |
Association Between Prehospital Tranexamic Acid Administration and Outcomes of Severe Traumatic Brain Injury.
Topics: Adult; Aged; Antifibrinolytic Agents; Brain Injuries, Traumatic; Cohort Studies; Emergency Medical S | 2021 |
Impact of tranexamic acid on coagulation and inflammation in murine models of traumatic brain injury and hemorrhage.
Topics: Animals; Anti-Inflammatory Agents; Antifibrinolytic Agents; Biomarkers; Blood Coagulation Disorders; | 2017 |
Optimisation of the dosage of tranexamic acid in trauma patients with population pharmacokinetic analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Brain Injuries, Traumatic; Drug | 2018 |
Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: an Austrian interdisciplinary consensus statement.
Topics: Administration, Oral; Anticoagulants; Austria; Brain Injuries, Traumatic; Consensus; Dabigatran; Dea | 2019 |
Tranexamic Acid Influences the Immune Response, but not Bacterial Clearance in a Model of Post-Traumatic Brain Injury Pneumonia.
Topics: Animals; Antifibrinolytic Agents; Brain Injuries, Traumatic; Disease Models, Animal; Immunity, Cellu | 2019 |
Using social media for community consultation and public disclosure in exception from informed consent trials.
Topics: Adolescent; Adult; Brain Injuries, Traumatic; Disclosure; Female; Human Experimentation; Humans; Inf | 2016 |